Chu C M, Chan V L, Lin A W N, Wong I W Y, Leung W S, Lai C K W
Division of Respiratory Medicine, Department of Medicine and Geriatrics, United Christian Hospital, Kowloon, Hong Kong, SAR, China.
Thorax. 2004 Dec;59(12):1020-5. doi: 10.1136/thx.2004.024307.
Non-invasive ventilation (NIV) has been shown to reduce intubation and in-hospital mortality in patients with chronic obstructive pulmonary disease (COPD) and acute hypercapnic respiratory failure (AHRF). However, little information exists on the outcomes following discharge. A study was undertaken to examine the rates of readmission, recurrent AHRF, and death following discharge and the risk factors associated with them.
A cohort of COPD patients with AHRF who survived after treatment with NIV in a respiratory high dependency unit was prospectively followed from July 2001 to October 2002. The times to readmission, first recurrent AHRF, and death were recorded and analysed against potential risk factors collected during the index admission.
One hundred and ten patients (87 men) of mean (SD) age 73.2 (7.6) years survived AHRF after NIV during the study period. One year after discharge 79.9% had been readmitted, 63.3% had another life threatening event, and 49.1% had died. Survivors spent a median of 12% of the subsequent year in hospital. The number of days in hospital in the previous year (p = 0.016) and a low Katz score (p = 0.018) predicted early readmission; home oxygen use (p = 0.002), APACHE II score (p = 0.006), and a lower body mass index (p = 0.041) predicted early recurrent AHRF or death; the MRC dyspnoea score (p<0.001) predicted early death.
COPD patients with AHRF who survive following treatment with NIV have a high risk of readmission and life threatening events. Further studies are urgently needed to devise strategies to reduce readmission and life threatening events in this group of patients.
无创通气(NIV)已被证明可降低慢性阻塞性肺疾病(COPD)合并急性高碳酸血症性呼吸衰竭(AHRF)患者的插管率和院内死亡率。然而,关于出院后的结局信息很少。本研究旨在调查出院后的再入院率、复发性AHRF和死亡率以及与之相关的危险因素。
对2001年7月至2002年10月期间在呼吸重症监护病房接受NIV治疗后存活的AHRF COPD患者队列进行前瞻性随访。记录再入院、首次复发性AHRF和死亡时间,并根据首次入院时收集的潜在危险因素进行分析。
在研究期间,110例患者(87例男性)平均(标准差)年龄73.2(7.6)岁,在接受NIV治疗后AHRF存活。出院一年后,79.9%的患者再次入院,63.3%的患者发生了另一次危及生命的事件,49.1%的患者死亡。幸存者在随后一年中有12%的时间住院。前一年的住院天数(p = 0.016)和低Katz评分(p = 0.018)预测早期再入院;家庭氧疗(p = 0.002)、急性生理与慢性健康状况评分系统II(APACHE II)评分(p = 0.006)和较低的体重指数(p = 0.041)预测早期复发性AHRF或死亡;医学研究委员会(MRC)呼吸困难评分(p<0.001)预测早期死亡。
接受NIV治疗后存活的AHRF COPD患者再入院和发生危及生命事件的风险很高。迫切需要进一步研究制定策略以降低该组患者的再入院率和危及生命事件的发生率。